Protective Activity of Ingavirin® in Experimental Lethal Influenza Due to Pandemic Influenza Virus A (H1N1)v (Albino Mice)

Abstract

Despite obvious success in the vaccine development and chemotherapy of influenza, it remains a poorly controlled infection leading to emergence of new pandemic variants of the virus with high morbidity and mortality. We investigated the protective activity of Ingavirin® against the lethal influenza A(H1N1)2009 virus infection on albine mice. Oral use of Ingavirin® resulted in sharp decreasing of the mortality (index of protection up to 57%), slight decreasing of the infectious titer of the virus in the lungs (up to 40-fold), normalizing of the body weight dynamics and the lung tissue structure vs. the placebo-treated control. The degree of the bronchial epithelium damage was also strongly decreased. The results allow to consider Ingavirin® as an effective antiviral against the current pandemic influenza virus.

Keywords

• influenza virus a (h1n1)
• albino mice
• ingavirin®